ArticleBrain and behavior2025
Citronellal Exerts Sedative-Like Effects and Augments Diazepam's Action in Swiss Mice, Possibly Through the GABAergic Pathway.
Article in Brain and behavior, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Gallic Acid-Mediated Enhancement of Diazepam-Induced Sedation via GABAFood science & nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCitronellal (CTL), a monoterpenoid, exhibits notable neurological activity, including anxiolytic, and anticonvulsant effects, primarily through GABAergic pathways. Our current study aimed to explore CTL's sedative potential using in vitro, in vivo, and in silico approaches through the GABAergic pathway.
methodsThe in vitro GABAergic activity of CTL was assessed via colorimetric assay, while acute toxicity was evaluated in Swiss mice per OECD guidelines with doses up to 2000 mg/kg to establish safety margins. Sedative effects were assessed in Swiss mice using thiopental sodium (TS, 40 mg/kg)-induced sleep protocols. CTL was administered at 62.5, 125, and 250 mg/kg doses, alone or combined with diazepam (DZP, 2 mg/kg) or flumazenil (FLU, 0.1 mg/kg). The in silico studies were also performed with GABA
resultsThe results demonstrated that in vitro, CTL exhibited significantly concentration-dependent GABAergic activity. Acute toxicity tests indicated a high safety margin (no behavioral or physiological abnormalities at 2000 mg/kg dose). Additionally, CTL significantly (p < 0.05) and dose-dependently reduced the latency and augmented sleep duration in animals, compared to the control group. It also significantly (p < 0.05) decreased the latency and increased the duration of sleep with DZP-2 while reducing this parameter with FLU-0.1. In in silico studies, CTL exhibited binding affinities (BAs) with the GABA
conclusionCTL demonstrated potent sedative effects in vitro and in vivo, with a strong safety profile and interaction with the GABA
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.